Literature DB >> 16682965

Opioid and cannabinoid receptors: friends with benefits or just close friends?

MacDonald J Christie1.   

Abstract

mu-Opioid (MOP) and cannabinoid CB1 receptors mediate overlapping pharmacological responses in clinically important areas such as drug abuse and pain management, and functional interactions between agonists at these receptors have long been recognized. In the present issue of this Journal, Rios and co-workers have provided the first strong evidence that the two receptors interact directly when coexpressed in the same cells. The authors report a close physical association between MOP and CB1 receptors and novel pharmacological interactions of MOP and CB1 agonists. They argue that MOP/CB1 heterodimer formation explains these interactions. If correct, the direct interaction of MOP and CB1 pharmacophores in a quaternary complex would provide real benefits by opening the potential for development of novel MOP/CB1 small molecules or new strategies for use of current ligands. However, a lot more evidence will be required before the heterodimer interpretation can be accepted. If it turns out that MOP and CB1 receptors do not readily form hetero-oligomers, the study by Rios and co-workers shows that they are still friends but there may be few benefits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682965      PMCID: PMC1751787          DOI: 10.1038/sj.bjp.0706756

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

Review 1.  G-protein-coupled receptor dimerization: modulation of receptor function.

Authors:  C D Rios; B A Jordan; I Gomes; L A Devi
Journal:  Pharmacol Ther       Date:  2001 Nov-Dec       Impact factor: 12.310

2.  Functional interactions between mu opioid and alpha 2A-adrenergic receptors.

Authors:  B A Jordan; I Gomes; C Rios; J Filipovska; L A Devi
Journal:  Mol Pharmacol       Date:  2003-12       Impact factor: 4.436

Review 3.  Selectivity in the oligomerisation of G protein-coupled receptors.

Authors:  Graeme Milligan; Juan Lopez-Gimenez; Shirley Wilson; Juan J Carrillo
Journal:  Semin Cell Dev Biol       Date:  2004-06       Impact factor: 7.727

Review 4.  Methods to monitor the quaternary structure of G protein-coupled receptors.

Authors:  Graeme Milligan; Michel Bouvier
Journal:  FEBS J       Date:  2005-06       Impact factor: 5.542

5.  mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis.

Authors:  Carl Rios; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

Review 6.  Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET).

Authors:  Kevin D G Pfleger; Karin A Eidne
Journal:  Nat Methods       Date:  2006-03       Impact factor: 28.547

7.  Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Authors:  David J Daniels; Natalie R Lenard; Chris L Etienne; Ping-Yee Law; Sandra C Roerig; Philip S Portoghese
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

8.  Interaction of bivalent ligand KDN21 with heterodimeric delta-kappa opioid receptors in human embryonic kidney 293 cells.

Authors:  Zhihua Xie; Rashmi G Bhushan; David J Daniels; Philip S Portoghese
Journal:  Mol Pharmacol       Date:  2005-07-08       Impact factor: 4.436

9.  Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation.

Authors:  B A Jordan; N Trapaidze; I Gomes; R Nivarthi; L A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

  9 in total
  5 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Optogenetic identification of an intrinsic cholinergically driven inhibitory oscillator sensitive to cannabinoids and opioids in hippocampal CA1.

Authors:  Daniel A Nagode; Ai-Hui Tang; Kun Yang; Bradley E Alger
Journal:  J Physiol       Date:  2013-11-04       Impact factor: 5.182

3.  Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus.

Authors:  E Soria-Gómez; I Matias; P E Rueda-Orozco; M Cisneros; S Petrosino; L Navarro; V Di Marzo; O Prospéro-García
Journal:  Br J Pharmacol       Date:  2007-06-04       Impact factor: 8.739

Review 4.  U.S. Policy Responses to Calls for the Medical Use of Cannabis.

Authors:  Wayne Hall
Journal:  Yale J Biol Med       Date:  2015-09-03

5.  Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results.

Authors:  Cristina Fernández-Fernández; Luis F Callado; Rocío Girón; Eva Sánchez; Amaia M Erdozain; José Antonio López-Moreno; Paula Morales; Fernando Rodríguez de Fonseca; Javier Fernández-Ruiz; Pilar Goya; J Javier Meana; M Isabel Martín; Nadine Jagerovic
Journal:  Drug Des Devel Ther       Date:  2014-02-20       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.